[1] Kushima R.The updated WHO classification of digestive system tumours-gastric adenocarcinoma and dysplasia[J]. Pathologe, 2022,43(1):8-15.
[2] Gu Y J, Zhu Y Y, Lu X Y, et al. Hepatic carcinosarcoma: evidence of polyclonal origin based on microsatellite analysis[J]. Pathol Res Pract,2015,211(12):905-910.
[3] Xiang S, Chen Y F, Guan Y, et al. Primary combined hepatocellular-cholangiocellular sarcoma: an unusual case[J]. World J Gastroenterol, 2015;21(23):7335-7342.
[4] 余捷,林达,胡明哲,等.16例原发性肝肉瘤样癌CT与MRI表现特点分析[J].中华肝胆外科杂志,2020,26(3):183-186.
[5] Liao S-H, Su T-H, Jeng Y-M, et al. Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma[J]. Hepatology, 2019, 69(1): 209-221.
[6] Wang Q B, Cui B K, Weng J M,et a1.Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver[J].J Gastrointest Surg,2012,16(9):1715-1726.
[7] 屠金夫,阮小蛟,李剑敏,等.肝内胆管肉瘤样癌一例[J].中华普通外科杂志,2010,25(6):510-511.
[8] Amarapurkar AD,Viblmv,Kun V. Angingenesis in liver cirrhosis and hepatocelhlar carcinoma[J]. Indian J Pathol Microbiol, 2008,51(3):323-328.
[9] Li J, Liang P, Zhang D, et al. Primary carcinosarcoma of the liver: imaging features and clinical findings in six cases and a review of the literature[J]. Cancer Imaging,2018;18(1):7-15.
[10] Zhu S G, Li H B, Yuan Z N, et al. Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma: a case report[J]. World J Gastrointest Oncol, 2020 ,12(10):1209-1215.
[11] Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer[J].Am J Cancer Res,2020,10(1):727-742.
[12] 郑桂丽,梁秀菊,董敏,等.PD-1抑制剂联合FOLFOX4化疗方案治疗晚期胃癌的效果[J].中国医药导报,2021,18:98-101.
[13] 谭永华,蔡江霞,刘慧利,等.信迪利单抗治疗中晚期肝细胞癌的疗效及安全性[J]. 介入放射学杂志,2023,32(8):750-754.
[14] Morisue R, Kojima M, Suzuki T, et al. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: clinicopathologic, transcriptomic and immunologic analyses[J]. Int J Cancer,2021,149(3):546-560. |
